Cell-based cardiac repair following myocardial infarction has gained considerable interest recently, and the human pluripotent stem cell is an attractive cell source due its efficient differentiation into immature but functional cardiomyocytes. We examined the biophysical characteristics of cardiomyocytes generated from human embryonic stem cells (hESC-CMs) by measuring calcium transients, single cell contractions, and actomyosin interactions via flash photolysis. Furthermore, we compared these characteristics with those obtained from a second promising but still poorly characterized cell type, the human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM). We hypothesized that understanding fundamental biochemical and mechanical characteristics of these cells would provide insight into potential strategies to induce further cell maturation in vitro.Our results suggest that hESC-CMs and hiPSC-CMs exhibit spontaneous contractions and calcium transients with similar kinetics, including time to peak [Ca2+]i (116±34ms vs. 155±40ms) and time to 50% [Ca2+]i decay (352±87ms vs. 296±49ms). Furthermore, quantitative videomicroscopy of resulting single cell contractions suggests that cardiomyocytes from both sources demonstrate similar resting cell size (17.1±1.4um vs. 16.5±4.6um), contraction amplitude (4.2±1.6% vs. 4.4±2.1%), time to peak contraction (0.346±0.135sec vs. 0.339±0.214sec), maximum contraction velocity (6.34±3.50um/sec vs. 7.46±4.81um/sec), and maximum relaxation velocity (3.21±2.49um/sec vs. 3.40±2.49um/sec).We have also successfully isolated and purified 20 ug of myosin per million hESC-CMs. Using flash photolysis to liberate ATP in a solution of actomyosin, we have shown that the myosin binds actin and is dissociated from the complex by ATP with the expected 2nd order rate constant (∼1 uM−1sec−1).In summary, the contractile properties of hESC-CMs and hiPSC-CMs are similar to each other but differ from values published for adult human cardiomyocytes, suggesting that they are functionally immature and may benefit from in vitro maturation efforts.Support appreciated from NIH HL064387/HL080431, NHLBI T32GMO7266-35S1, and the Wellcome Trust.